Non-Small Cell Lung Cancer Coverage from Every Angle
Editor:
David S. Ettinger, MD, FACP, FCCP
Advertisement
Advertisement

Available Clinical Trials

A Phase I Study of NVL-655 in People With Advanced NSCLC or Other Solid Tumors
A Phase II Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic NSCLC
A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic NSCLC
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab vs Standard of Care in Stage IV or Recurrent NSCLC
A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs Placebo for Patients With Tumors Harboring the ALK Fusion Protein
A Phase III Study Assessing the Addition of Atezolizumab Immunotherapy to the Usual Radiation Treatment for Patients With Early NSCLC
A Phase III, Randomized, Placebo-Controlled Clinical Study of SBRT With or Without Pembrolizumab in Participants With Medically Inoperable NSCLC (KEYNOTE-867)
A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter, International Study of Durvalumab With SBRT for the Treatment of Patients With Unresected Stage I/II, Lymph Node–Negative NSCLC
A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I NSCLC With Primary Tumors Between 1 and 4 cm:
A Randomized, Open-label, Phase II Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naive Subjects With Advanced or Metastatic PD-L1 High NSCLC Without Actionable Genomic Alterations
A Study Comparing X-396 (Ensartinib) to Crizotinib in Patients With ALK Positive NSCLC
A Study of Poziotinib in Patients With NSCLC With EGFR or HER2 Exon 20 Insertion Mutation
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I NSCLC With Primary Tumors Between 1–4 cm
AMG510 w/Positive Stage IV or Recurrent KRAS G12C NSCLC (Lung-Map Substudy)
An Open-Label, Multicenter, Phase II Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
An Open-Label, Randomized, Multicenter, Phase III Study of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations
Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced NSCLC
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Fred and Pamela Buffett Cancer Center
Huntsman Cancer Institute at the University of Utah
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
LATIFY: Ceralasertib Plus Durvalumab vs Docetaxel in NSCLC Whose Disease Progressed on or After Prior Anti–PD(L)1 Therapy and Platinum-Based Chemotherapy
Osimertinib With or Without Bevacizumab as Initial Treatment of EGFR-Mutant Lung Cancer
Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Nonsquamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
Phase III Randomized Trial Comparing Overall Survival After Photon vs Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Study of Avutometinib (VS-6766) Plus Adagrasib in KRAS G12C NSCLC Patients
SWOG 1900F: A Randomized Phase II Study of Carboplatin and Pemetrexed With or Without Selpercatinib in Nonsquamous RET Fusion-Positive Stage IV NSCLC
Testing the Addition of Atezolizumab to the Usual Radiation Treatment for Patients With Early NSCLC
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC
The University of Texas MD Anderson Cancer Center
University of Michigan Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.